NEW YORK (GenomeWeb) – CareDx's shares soared as high as 34 percent in morning trading on the Nasdaq after the company announced that Palmetto GBA's Molecular Diagnostics Services (MolDX) Program had set reimbursement for the firm's AlloSure cfDNA-based organ transplant test diagnostic at $2,840.75.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.